Valuation: CorMedix Inc.

Market Cap 566M 504M 466M 424M 799M 53.73B 812M 5.6B 2.21B 28.02B 2.12B 2.08B 89.32B P/E 2026 *
14.7x
P/E 2027 * 128x
Enterprise Value 456M 407M 376M 342M 645M 43.34B 655M 4.52B 1.78B 22.6B 1.71B 1.68B 72.05B EV / Sales 2026 *
1.35x
EV / Sales 2027 * 1.45x
Free-Float
92.39%
Yield 2026 *
-
Yield 2027 * -
1 day-2.68%
1 week-1.63%
Current month-5.71%
1 month-6.80%
3 months-13.78%
6 months-1.76%
Current year-37.58%
1 week 7.16
Extreme 7.1568
7.7
1 month 7.06
Extreme 7.055
8.18
Current year 6.12
Extreme 6.125
12.29
1 year 6.12
Extreme 6.125
13.02
3 years 2.57
Extreme 2.57
17.43
5 years 2.57
Extreme 2.57
17.43
10 years 0.86
Extreme 0.8605
18.8
Manager TitleAgeSince
Chief Executive Officer 50 09/05/2022
Director of Finance/CFO 54 28/08/2025
Compliance Officer 66 11/12/2023
Director TitleAgeSince
Director/Board Member 67 05/08/2015
Chairman 81 02/08/2017
Director/Board Member 70 15/08/2011
Date Insider Type Main position Quantity % Market Cap. Importance
18/09/26 Exercice

Director

97,818 0.1255%
29/08/26 Tax

Chief Financial Officer

-8,424 0.0108%
29/08/26 Tax

Compliance Officer

-8,424 0.0108%
Change 5-day change 1-year change 3-year change Capi.($)
-2.68%-1.63%-28.68%+111.66% 566M
+0.43%+6.59%+56.57%+106.64% 1,120B
+0.90%-2.25%+32.26%+63.73% 616B
+0.71%+3.24%+24.33%+91.33% 504B
-0.13%+5.98%+33.66%+50.18% 367B
+0.52%+0.24%+72.13%+40.11% 360B
-0.95%+4.70%+19.65%+42.71% 288B
-1.98%+3.73%-0.89%+10.43% 258B
-0.35%+4.25%+44.74%+52.06% 234B
-0.75%+3.32%+27.18%+94.07% 194B
Average -0.43%+3.09%+28.10%+66.29% 394.15B
Weighted average by Cap. +0.13%+3.83%+39.33%+71.83%

Financials

2026 *2027 *
Net sales 337M 300M 278M 253M 476M 32B 484M 3.34B 1.31B 16.69B 1.26B 1.24B 53.21B 289M 258M 238M 217M 408M 27.47B 415M 2.86B 1.13B 14.32B 1.09B 1.06B 45.66B
Net income 45.67M 40.68M 37.62M 34.25M 64.48M 4.34B 65.54M 452M 178M 2.26B 171M 168M 7.21B 5.33M 4.75M 4.39M 4M 7.53M 506M 7.65M 52.74M 20.79M 264M 20M 19.57M 841M
Net Debt -109M -97.47M -90.14M -82.06M -155M -10.39B -157M -1.08B -427M -5.42B -411M -402M -17.27B -147M -131M -121M -110M -208M -13.99B -211M -1.46B -575M -7.3B -553M -541M -23.26B
Projected Income Statement - Annual - CorMedix Inc.
Logo CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Employees
191
Date Price Change Volume
16/10/26 US$7.260 -2.68% 1,140,589
15/10/26 US$7.460 +0.95% 1,466,252
14/10/26 US$7.390 0.00% 1,124,915
13/10/26 US$7.390 -0.94% 1,415,670
12/10/26 US$7.460 +1.08% 1,592,037
Trader
Investor
Global
Quality
-
ESG MSCI
BB
MarketScreener Ratings - CorMedix Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
7.260USD
Average target price
15.33USD
Spread / Average Target
+111.20%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - CorMedix Inc.
  1. Stock Market
  2. Stocks
  3. CRMD Stock